KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of ...

Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the session Mini Oral session 2: GU tumours, renal & urothelial Dr. Tian Zhang ...

Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. This is an ASCO Meeting Abstract from the 2025 ...

During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows ...

Limited (“ HUTCHMED ”) (Nasdaq/AIM:?HCM; HKEX:?13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and sintilimab combination for the treatment of patients with ...

Metastasis-directed treatment (MDT) for patients (pts) with non-clear cell renal cell carcinoma (nccRCC): Results from a matched 15-year retrospective cohort. Metastatic renal cell carcinoma (mRCC) ...

Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab ...